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Abstract
Background: Germline mutations in BRCA1 and BRCA2 predispose to breast and ovarian cancer.
A multitude of mutations have been described and are found to be scattered throughout these two
large genes. We describe analysis of BRCA1 in 25 individuals from 18 families from a Greek cohort.
Methods: The approach used is based on dHPLC mutation screening of the BRCA1 gene, followed
by sequencing of fragments suspected to carry a mutation including intron – exon boundaries. In
patients with a strong family history but for whom no mutations were detected, analysis was
extended to exons 10 and 11 of the BRCA2 gene, followed by MLPA analysis for screening for large
genomic rearrangements.
Results: A pathogenic mutation in BRCA1 was identified in 5/18 (27.7 %) families, where four
distinct mutations have been observed. Single base putative pathogenic mutations were identified
by dHPLC and confirmed by sequence analysis in 4 families: 5382insC (in two families), G1738R,
and 5586G > A (in one family each). In addition, 18 unclassified variants and silent polymorphisms
were detected including a novel silent polymorphism in exon 11 of the BRCA1 gene. Finally, MLPA
revealed deletion of exon 20 of the BRCA1 gene in one family, a deletion that encompasses 3.2 kb
of the gene starting 21 bases into exon 20 and extending 3.2 kb into intron 20 and leads to skipping
of the entire exon 20. The 3' breakpoint lies within an AluSp repeat but there are no recognizable
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repeat motifs at the 5' breakpoint implicating a mechanism different to Alu-mediated recombination,
responsible for the majority of rearrangements in the BRCA1 gene.
Conclusions: We conclude that a combination of techniques capable of detecting both single base
mutations and small insertions / deletions and large genomic rearrangements is necessary in order
to accurately analyze the BRCA1 gene in patients at high risk of carrying a germline mutation as
determined by their family history. Furthermore, our results suggest that in those families with
strong evidence of linkage to the BRCA1 locus in whom no point mutation has been identified re-
examination should be carried out searching specifically for genomic rearrangements.
Background
Germ line mutations in the BRCA1 and BRCA2 genes pre-
dispose individuals to breast and ovarian cancer. The life-
time risk of breast cancer in female carriers of a BRCA1
mutation is 60–80% while that of ovarian cancer is 20–
40%. The median age of diagnosis of breast cancer is 42
years, i.e. 20 years earlier than the median of unselected
women in the U.S.A. and Western Europe [1]. BRCA1 is a
large gene with 22 coding exons encoding a 220 kD pro-
tein [2] that functions in maintaining genomic integrity
and in transcriptional regulation [3,4].
A multitude of mutations scattered throughout the 5592
bp coding sequence have been described. In particular,
germ line mutations in BRCA1 have been identified in
15–20% of women with a family history of breast cancer
and 60–80% of women with a family history of breast and
ovarian cancer [5,6]. The percentage of mutations identi-
fied is strongly dependent on the population studied,
with strong founder effects evident in some populations
[7-9]. The vast majority of mutations described to date are
point mutations and small insertions and deletions http:/
/research.nhgri.nih.gov/bic/. Such mutations are detected
by PCR-based screening methods such as the Protein
Truncation Test (PTT), Single Strand Conformational Pol-
ymorphism (SSCP), Denaturing Gradient Gel Electro-
phoresis (DGGE), heteroduplex analysis (HA) and more
recently denaturing high performance liquid chromatog-
raphy (dHPLC) with varying degrees of sensitivity for each
method. Direct DNA sequencing is used in order to con-
firm and characterize mutations detected by any of these
approaches [10,11]. While in the early studies for muta-
tion detection only single point or small insertion/dele-
tion mutations were screened for, recent studies have
shown that genomic rearrangements are also a common
type of mutation in the two genes accounting for 10–30 %
of all mutations identified in some populations [12-16].
In this study we document and extend previous work sug-
gesting the necessity of screening for large genomic rear-
rangements in a complete program for mutation detection
of the BRCA1 gene by characterizing a deletion encom-
passing 3.2 kb of the gene including exon 20. In addition,
we add more evidence supporting pathogenicity of a pre-
viously described variant, G1738R, which seems to be
specific to the Greek population [17].
Methods
Patients
BRCA1 patients and their families were referred through
the Oncology Departments of Hygeia Hospital and other
hospitals throughout Greece. Patients were included on
the basis of affected family members, types of cancer
present in the family and the age at diagnosis of breast
cancer in the proband. The families were subdivided into
high risk when multiple cases of breast and ovarian cancer
were diagnosed, medium risk if there were only 2–3 cases
of breast cancer, and low risk in isolated cases of breast
cancer with diagnosis before the age of 40 years. The study
population consisted therefore of 12 high risk families, 2
with medium risk, and 4 families at low risk as deter-
mined by their cancer history. Ethical approval was
obtained from the hospital's advisory committee and all
patients signed informed consent. Screening has been
completed in 25 individuals from 18 families. Testing was
initially carried out on DNA from an affected family mem-
ber and upon detection of an inactivating mutation the
rest of the family members were directly tested for this
mutation.
DNA and RNA isolation
Genomic DNA and RNA were purified from peripheral
blood leukocytes using standard extraction protocols.
PCR amplification
The complete coding sequence of BRCA1 including splice
junctions was amplified by PCR. Similarly, exons 10 and
11 of the BRCA2 gene were amplified in 3 of the patients.
Primers used have been chosen from the BIC database
http://www.nhgri.nih.gov/Intramural_research/
Lab_transfer/Bic/. In addition primers: mBRCAF: GAG
TTT GTG TGT GAA CGG ACA CTG and mBRCAR: GTG
CCA AGG GTG AAT GAT GAA AGC, designed during the
course of this study, were used for amplification of cDNA
from the patients found to carry a deletion of exon 20 of
the BRCA1 gene.BMC Cancer 2004, 4:61 http://www.biomedcentral.com/1471-2407/4/61
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Reactions of 50 µl were heated on a PTC-200 MJ Research
Thermocycler (MJ Research Inc., USA) at 95°C for 5 min
then cycled 35 times of denaturation at 95°C for 40 sec,
annealing at the appropriate temperature for 30 sec and
extension at 72°C for 30 sec, followed by a final extension
step at 72°C for 6 min. Reaction mixture was 20 mM
TrisHCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl2, 200 µM
each dNTP, 1.5 U Taq DNA polymerase (Invitrogen, Neth-
erlands) or 2.5 U Optimase polymerase (Transgenomic,
Inc., USA) and 12.5 pmol of each primer.
dHPLC analysis
The WAVE DNA Fragment Analysis System (Transge-
nomic, Inc., USA) and associated WAVE-Maker™ software
were used as previously described [18].
Sequence analysis
Purification of the PCR products was performed using the
Concert Rapid PCR purification or gel extraction system
kits (Marligen Biosciences INC, U.S.A.). Automated cycle
sequencing for both strands was performed with the ABI
Prism® 310 Genetic Analyzer using the Big-Dye Termina-
tor Cycle Sequencing Kit. Sequences obtained were
aligned, using Sequencher®  PC software, with normal
sequences from Genbank (BRCA1: L78833, BRCA2:
U43746) and examined for the presence of mutations. All
nucleotide numbers refer to the wild-type cDNA sequence
of  BRCA1  as reported in GenBank (accession number
U14680).
Multiplex Ligation – dependent PCR Amplification 
(MLPA)
MLPA was carried out using the P002_BRCA1 kit (MRC-
Holland, Netherlands) as instructed by the manufacturer.
Fragment analysis was carried out on ABI Prism® 310
Genetic Analyzer (Applied Biosystems, USA) using
TAMRA-500 (Applied Biosystems, USA) as size standard.
A peak pattern of 34 peaks ranging in size from 127 to 454
nt is obtained [19].
Long PCR
The deletion in BRCA1 exon 20 was confirmed by long
PCR using the GeneAmp XL PCR System (Applied Biosys-
tems, U.S.A.) according to the manufacturer's instruc-
tions. PCR was carried out in 50 µl reactions consisting of
1 × buffer II (supplied with the enzyme), 12 pmole each
primer, 0.2 mM each dNTP and 2.4 U rTth DNA polymer-
ase, XL (Applied Biosystems, U.S.A.). After 2.5 min dena-
turation at 95°C PCR was carried out for 19 cycles of 95°C
for 30 sec, 58°C for 30 sec and 68°C for 8 min followed
by 15 cycles of 95°C for 30 sec, 58°C for 30 sec and 68°C
for 4 min with a time increment of 10 sec per cycle. A final
extension step was carried out at 72°C for 10 min. PCR
products were separated by agarose gel electrophoresis
and visualized by EtBr staining.
RT-PCR
Total RNA was extracted from whole blood of patients
from family D using Trizol (Life Technologies, USA)
according to the manufacturer's instructions. First strand
synthesis was performed by denaturing approximately
500 – 1000 ng total RNA, random hexamers (5 µM final
concentration) for 4 min at 70°C, followed by snap freez-
ing on ice and addition of dNTPs (0.5 mM final concen-
tration), 1 U/µl recombinant RNase inhibitor (Invitrogen,
Netherlands) and 200 U MMLV reverse transcriptase (Inv-
itrogen, Netherlands). The mixture was incubated at 37°C
for 1 hour followed by denaturation of the enzymes at
95°C for 5 min. 4 µl of cDNA were used for subsequent
PCR amplification.
Results
A total of 18 families, 12 of which were at high risk of hav-
ing hereditary breast cancer, have been examined for
mutations at the BRCA1  locus. A pathogenic mutation
was identified in five families, where four distinct muta-
tions have been observed. In addition, 18 polymor-
phisms, including a novel silent polymorphism in exon
11 of the BRCA1 gene, have been detected (Table 1). Fur-
thermore, in 3 of the families exons 10 and 11 of BRCA2
were analyzed. Table 1 summarizes the results of single
nucleotide variants detected in this study. All of the vari-
ants have been identified by dHPLC and characterized by
sequencing.
In family A there were four cases of breast cancer affecting
four successive generations. The proband was diagnosed
with breast cancer at the age of 45. The most frequently
occurring mutation, 5382insC in exon 20, was identified.
Analysis of the proband's daughter in whom cancer devel-
oped at the age of 38 revealed that she also carried the
mutation. The same mutation was also identified in fam-
ily E where breast cancer was diagnosed in 3 members in
three successive generations at 42, 37 and 41 years (data
not shown).
In family B there were seven cases of breast cancer and one
case of colorectal cancer at age 50. Mutation analysis at the
BRCA1 locus revealed a missense mutation 5331 G > A.
The mutation results in substitution of a Glycine by an
Arginine at codon 1738. The mutation was not detected in
the patient's unaffected sister. Unfortunately, no other
family members were available for analysis.
In family C there were 4 cases of breast cancer in addition
to cancer of the larynx, ovaries, lung and the genitals. A
single base substitution, G > A at nucleotide 5586 was
identified. This mutation causes a splicing defect resulting
in a protein lacking exon 23. Unfortunately, no DNA was
available from other family members in order to test the
correlation of this mutation with the other tumor types.BMC Cancer 2004, 4:61 http://www.biomedcentral.com/1471-2407/4/61
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In Family D (Figure 1a) there were 5 cases of breast cancer
with age at onset ranging from 29 to 50 years. In addition
there was one individual who had CRC. Sequencing of the
complete coding region of BRCA1, failed to reveal a muta-
tion. This prompted the analysis of other genes, namely
BRCA2 and p53 in order to try and characterize the phe-
notype in this family, but no mutation was identified. For
this reason, we decided to use the MLPA technique [19] to
screen the proband for genomic rearrangements which
have been shown to be responsible for a large proportion
of  BRCA1  mutations. MLPA analysis of the proband
(IV:10 in figure 1a) revealed deletion of exon 20 of the
BRCA1 gene. This was confirmed by Long PCR (Figure 1b)
and RT – PCR. Sequencing of PCR products generated by
RT-PCR confirmed absence of the entire exon 20 in the
mRNA of the patient. Subsequently, a number of restric-
tion endonucleases were employed in order to narrow
down the deletion breakpoints and facilitate their charac-
terization. A SmaI-generated irregular fragment was finally
isolated from agarose gel and sequenced revealing a dele-
tion of 3.2 kb starting 21 bases into exon 20 and extend-
ing 3.2 kb into intron 20 (Figure 1c). The 3' breakpoint
lies within an AluSp repeat but there are no recognizable
repeat motifs at the 5' breakpoint. The deletion was also
found in 4 relatives of the proband (Figure 1a) who were
tested, two of whom had breast cancer. The other two
relatives had not yet developed cancer at the ages of 36
and 55 at the time of testing and are therefore assumed to
be pre – symptomatic carriers. Finally, the proband's sis-
ter, who at the time of testing had not developed cancer at
the age of 33 was found not to carry the mutation.
Table 1: Variants identified in the BRCA1 and BRCA2 genes during this study.
Mutation
Family No Total No of CaBr1 No of CaOv2 cases Exon Nucleotide Effect Other cancers             
(age at onset)
A 4 - 20 5382ins C Fs3 -
B 7 - 20 5331 G > A G1738R Colorectal (50)
C 4 1 23 5586G > A Splicing Larynx Lungs Genitalia
D 5 - 20 Deletion of the 
entire exon
Protein missing 20 a.a. of 
the BRCT-linker domain
Colorectal
E 3 - 20 5382ins C Fs3 -
Benign polymorphisms
Exon Codon Nucleotide Change Consequences No of families
BRCA1 IVS 4 IVS4-19 C > A - 1
IVS 7 IVS7-34 C > T - 2
11 693 2196G > A Asp > Asn 2
694 2201C > T Ser > Ser 5
771 2430T > C Leu > Leu 6
871 2731C > T Pro > Leu 3
1038 3232A > G Glu > Gly 7
1040 3238G > A Ser > Asn 1
11454 3544T > C Val > Val 1
1150 3567C > T Pro > Ser 1
1183 3667A > G Lys > Arg 7
13 1436 4427T > C Ser > Ser 4
16 1613 4956A > G Ser > Gly 1
24 1829 5606G > A Glu > Glu 2
BRCA2 10 372 1342A > C Asn > His 1
11 1132 3624A > G Lys > Lys 2
1269 4053T > C Val > Val 1
14 2414 7470A > G Ser > Ser 1
1 CaBr = Breast Cancer
2 CaOv = Ovarian Cancer
3 fs = frame-shift mutation
4 novel polymorphism identified in this studyBMC Cancer 2004, 4:61 http://www.biomedcentral.com/1471-2407/4/61
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Family D in whom deletion of exon 20 of the BRCA1 gene was detected Figure 1
Family D in whom deletion of exon 20 of the BRCA1 gene was detected. a. Pedigree of family D. Black symbols indicate individ-
uals with cancer. The proband is indicated by an arrow. A red circle inside a symbol indicates individuals found to carry the 
mutation. (CaBr=breast cancer, CRC=colorectal cancer d.=age of death, N=individual tested for the family mutation and was 
found to be of normal genotype). b. Long PCR of DNA from three individuals in family D. (M=molecular size marker (λ/HindIII, 
New England Biolabs, U.S.A.), C=normal control, numbers denote the identifier in the pedigree). c. Schematic representation 
(not to scale) of the fragment of BRCA1 gene amplified by Long PCR showing the position of exons, restriction endonuclease 
cleavage sites and the deletion. Empty boxes indicate exons. Vertical colored bars indicate restriction sites: blue (S) = SmaI. 
Red (H) = HindIII.BMC Cancer 2004, 4:61 http://www.biomedcentral.com/1471-2407/4/61
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Discussion
A total of 18 breast cancer families have been examined
for mutations at the BRCA1 locus. In three of the families
analysis was extended to exons 10 and 11 of the BRCA2
gene. A pathogenic mutation in BRCA1 was identified in
5/18 (27.7 %) families, where four distinct mutations
have been observed. In addition, 18 polymorphisms have
been found to be present in more than one family.
In family B a missense mutation, 5331 G > A, was identi-
fied. The exact effect of this single amino acid change,
G1738R, on the protein function is unclear. The altered
glycine is located on the surface of the coil structure of the
BRCT linker region and the mutation therefore may dis-
rupt the interface or affect protein interaction [20]. This
mutation has been previously described in 4 unrelated
Greek patients [21]. An alternative mutation affecting the
same amino acid, G1738E, has been shown to result in
loss of function of the protein in vitro [22,23]. Based on
this information, the family history of the individual
described here and absence of the mutation in the
proband's unaffected sister we hypothesize that the muta-
tion is pathogenic although additional data are needed.
Our results indicate, as has been documented by others
that family history is the major determinant of the risk of
breast cancer. As can be seen in Table 1 in all families
where a pathogenic mutation was identified there were at
least 3 cases of breast cancer. In addition, the extremely
high risk suggested by the family history in some cases
prompted a more intense analysis of further genes and
approaches in an attempt to characterize the underling
reason for such a family history. This was the case in fam-
ily D where sequencing of the complete coding region of
BRCA1, failed to reveal a mutation. This prompted the
analysis of other genes, namely BRCA2 and p53, but with-
out finding a mutation. For this reason, we decided to use
the MLPA technique [19] to screen the proband for
genomic rearrangements which have been shown to be
responsible for a large proportion of BRCA1 mutations
[12-16]. This led to the identification of deletion of an
entire exon of the BRCA1 gene, namely exon 20.
Deletion of exon 20 has been previously described in an
Italian family [12]. However, the authors of that report
have localized the breakpoints of the deletion in the two
flanking introns [12]. In the deletion described here the 5'
breakpoint is localized inside exon 20 (21 bp upstream of
the splice donor site) while the 3' breakpoint is located
3.2 kb into intron 20 within an AluSp repeat. The deletion
described here, therefore, is different to the majority of
rearrangements described so far for the BRCA1 gene, since
they have been shown to result from homologous recom-
bination of Alu repeats [24,25]. In this case, the 5' break-
point does not correlate with any recognizable repeat
motifs suggesting a repeat – independent recombination
mechanism at play.
In 2/5 pedigrees in whom a pathogenic mutation was
identified there was one case each of colorectal cancer
(CRC). In particular, in family D (Figure 1a) the disease
seems to have originated from a CRC patient. Data on the
correlation between BRCA1  mutations and the risk of
CRC are not conclusive. Two recent studies carried out on
Ashkenazi Jewish patients suggest that there is no correla-
tion [26,27]. Other reports carried out on more diverse
populations suggest 2- to 3-fold elevated risks of CRC
among first-degree relatives of BRCA1 mutation carriers
[28,29]. Unfortunately, there was no DNA available for
analysis from the two CRC patients in the two families.
A further interesting point observed in this study is the
identification of two BRCA1 unaffected mutation carriers
at the ages of 39 and 55. The penetrance and age of onset
of disease in BRCA1 mutation carriers is variable. Various
reports have suggested the existence of modifying genetic
and environmental factors on the penetrance of BRCA1
and BRCA2 mutation carriers [30,31]. In this respect it is
interesting to examine this large pedigree for such modi-
fying factors.
Conclusions
To our knowledge this is the first report of a genomic rear-
rangement identified as the underlying mutation of
BRCA1 in a Greek family. Although our sample group is
quite small identification of 1 genomic rearrangement in
5 mutations detected, suggests that in yet another popula-
tion this type of mutations contribute to the BRCA1 muta-
tion spectrum. This therefore warrants use of a
combination of techniques capable of identifying both
single base mutations in addition to large genomic rear-
rangements. In this respect, we have found that use of
dHPLC for single base mutations and MLPA for large
genomic rearrangements is a reliable combination for use
as an initial screening step followed by sequencing for
characterization of the mutations identified.
Furthermore, our results suggest that in those families
with strong evidence of linkage to the BRCA1 locus in
whom no point mutation has been identified re-examina-
tion should be carried out searching specifically for
genomic rearrangements.
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